JPS6045517A - １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 - Google Patents
１α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤Info
- Publication number
- JPS6045517A JPS6045517A JP14132483A JP14132483A JPS6045517A JP S6045517 A JPS6045517 A JP S6045517A JP 14132483 A JP14132483 A JP 14132483A JP 14132483 A JP14132483 A JP 14132483A JP S6045517 A JPS6045517 A JP S6045517A
- Authority
- JP
- Japan
- Prior art keywords
- 1alpha
- hydroxyvitamin
- antimyodystrophia
- agent containing
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 title claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- -1 1alpha-(OH)-D3 Chemical compound 0.000 abstract description 2
- 239000007891 compressed tablet Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- BDEDPKFUFGCVCJ-UHFFFAOYSA-N 3,6-dihydroxy-8,8-dimethyl-1-oxo-3,4,7,9-tetrahydrocyclopenta[h]isochromene-5-carbaldehyde Chemical compound O=C1OC(O)CC(C(C=O)=C2O)=C1C1=C2CC(C)(C)C1 BDEDPKFUFGCVCJ-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- UMFCIIBZHQXRCJ-NSCUHMNNSA-N trans-anol Chemical compound C\C=C\C1=CC=C(O)C=C1 UMFCIIBZHQXRCJ-NSCUHMNNSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132483A JPS6045517A (ja) | 1983-08-02 | 1983-08-02 | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132483A JPS6045517A (ja) | 1983-08-02 | 1983-08-02 | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6045517A true JPS6045517A (ja) | 1985-03-12 |
| JPH0319209B2 JPH0319209B2 (enExample) | 1991-03-14 |
Family
ID=15289273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14132483A Granted JPS6045517A (ja) | 1983-08-02 | 1983-08-02 | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6045517A (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996022779A1 (en) * | 1995-01-23 | 1996-08-01 | Zaidan Hojin Minsei Kagaku Kyokai | Muscular dystrophy progression depressant |
| CN103142476A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇混悬剂及其制备方法 |
| CN103142471A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇溶液剂及其制备方法 |
-
1983
- 1983-08-02 JP JP14132483A patent/JPS6045517A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996022779A1 (en) * | 1995-01-23 | 1996-08-01 | Zaidan Hojin Minsei Kagaku Kyokai | Muscular dystrophy progression depressant |
| CN103142476A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇混悬剂及其制备方法 |
| CN103142471A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇溶液剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0319209B2 (enExample) | 1991-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009047644A2 (en) | Method of treating vitamin d insufficiency and deficiency | |
| JP2001511768A (ja) | 活性型ビタミンｄ類似体を使用した前立腺疾患の治療方法 | |
| ES2437921T3 (es) | Método para prevenir la diabetes tipo 1 | |
| US20170252360A1 (en) | Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| JP2018502898A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 | |
| EP2651251A1 (en) | Composition for the treatment of metabolic disorders | |
| JPS6045517A (ja) | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 | |
| JP2007523162A (ja) | ２‐メチレン‐１９‐ノル‐２０（Ｓ）‐１α，２５‐ジヒドロキシビタミンＤ３の骨疾患の予防のための使用 | |
| JP2022133449A (ja) | レボドパ分割用量組成物および使用 | |
| JPS59116216A (ja) | アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤 | |
| US9814736B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| JPS60120812A (ja) | 糖尿病性骨減少症治療剤 | |
| JPH0474332B2 (enExample) | ||
| JPS63183534A (ja) | 乾癬治療剤 | |
| JPH0319208B2 (enExample) | ||
| JPH07233062A (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| Rado et al. | Metabolic bone disease (anticonvulsant osteomalacia) and renal tubular acidosis in tuberous sclerosis | |
| JPH05294834A (ja) | 活性型ビタミンｄ含有治療剤 | |
| WO1997016193A1 (en) | Pharmaceutical composition for treating osteoporosis | |
| JPH0377173B2 (enExample) | ||
| US20180055856A1 (en) | Combination of low dose 2-methylene-19-nor-(20s)-1alpha, 25-dihydroxyvitamin d3 and calcimimetics to treat secondary hyperparathyroidism | |
| JPH05194239A (ja) | 卵巣欠落によるのぼせ治療剤 | |
| JPH03169819A (ja) | １α―ヒドロキシビタミンＤ↓３類を含有する抗血栓症剤 | |
| JPH08507073A (ja) | カルシウム代謝障害の治療のための２６，２６，２６，２７，２７，２７−ヘキサフルオロ−１アルファ，２５−ジヒドロキシコレカルシフェロールの使用 |